Aytu BioPharma, Inc. AYTU
2.28
(0.03)
(1.30%)
as of 25 Sep
- Market cap
- $25.1M
- P/E
- 0.0×
Follow AYTU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (52.55%) | (97.24%) | (108.72%) | (49.33%) |
+8 more TTM periods Free account |
|
| (12.44%) | (28.87%) | (20.52%) | (10.86%) | ||
ROIC |
(19.99%) | (31.33%) | (106.20%) | (29.63%) | |
Return on Tangible Assets |
(190.36%) | (438.80%) | (218.98%) | (83.70%) | |
Average Days of Receivables |
144.42 | 157.93 | 180.19 | 190.39 | |
Free Cash Flow per Share |
0.26 | 0.15 | (0.06) | (0.14) | |
Free Cash Flow |
3.24 | 1.58 | (0.55) | (1.36) | |
Capital Expenditures |
(0.05) | (0.10) | 0.04 | — | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
4.17% | 2.01% | (0.91%) | (1.65%) | |
Accounts Receivable Turnover |
2.13 | 1.88 | 2.22 | 2.26 | |
Accounts Payable Turnover |
1.90 | 1.58 | 1.60 | 1.60 | |
Inventory Turnover |
2.27 | 2.15 | 2.10 | 1.89 | |
Average Days of Payables |
198.47 | 241.93 | 250.58 | 218.00 | |
Days of Inventory on Hand |
120.66 | 136.58 | 152.12 | 178.40 | |
Tax Rate |
0.03 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1.59% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
74.07% | 71.90% | 62.41% | 59.26% | |
Share Based Compensation of Revenue |
1.20% | 1.16% | 1.04% | 0.81% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.23) | (0.05) | 0.02 | 0.10 | |
Depreciation/Fixed assets |
10.50 | 10.77 | 9.40 | 9.91 | |
Capex/Depreciation |
(0.01) | (0.02) | 0.01 | 0.00 | |
Revenue per Share |
4.67 | 5.38 | 6.24 | 6.75 | |
Operating CF per Share |
0.27 | 0.16 | (0.06) | (0.14) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(24.76%) | (60.17%) | (39.02%) | (20.52%) |
Columns are period end dates · fundamentals updated 24 Sep 2026